Dominika M. Karaszewska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dominika M. Karaszewska has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Damiaan Denys
Department of Psychiatry, Amsterdam UMC, University of Amsterdam, The Netherlands
2 shared publications A. Lok
Department of Psychiatry, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
1 shared publicationAlbert F. G. Leentjens
Department of Psychiatry, Maastricht University Medical Centre, Maastricht, The Netherlands
1 shared publicationAnja Lok
Department of Psychiatry, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
1 shared publicationAnnemarie van Elburg
Faculty of Social Sciences, University of Utrecht, Utrecht, the Netherlands
1 shared publication- Annemiek Dols
Department of Psychiatry, UMC Utrecht Brain Center University Medical Center Utrecht Utrecht the Netherlands
1 shared publication
Latest Publications
- Open Access
- 13 May 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Barriers and facilitators to implementing deep brain stimulation for psychiatric disorders: a systematic review
Background Deep brain stimulation (DBS) is effective in treating severe obsessive-compulsive disorder (OCD) and treatment-resistant depression (TRD). However, patient referrals for DBS remain lower than expected based on prevalence and eligibility. Understanding the factors behind this gap is crucial for improving DBS implementation. This study aimed to identify key barriers and facilitators influencing DBS use for OCD and TRD. Insights from this research may help policymakers and clinicians address challenges, ultimately enhancing DBS accessibility and effectiveness for psychiatric disorders. Methods A systematic review was performed using four electronic databases until May 1st 2024 following PRISMA and ENTREQ guidelines. Eligible for inclusion were quantitative and qualitative studies describing facilitators or barriers for implementing DBS in psychiatry. Results We included 28 studies, out of which 11 in TRD, 5 in OCD and 12 in both, and revealed a spectrum of barriers, including ethical concerns, safety issues, stigma and knowledge gaps. Promising facilitators include educational initiatives, specialized psychiatric DBS care and stakeholder engagement. Discussion This first systematic review provides a comprehensive overview of barriers and facilitators affecting DBS implementation for OCD and TRD. Key areas include establishing consensus on treatment resistance, refining referral guidelines, addressing knowledge gaps among clinicians—such as psychiatrists unfamiliar with neurosurgical psychiatric treatments—and improving DBS’s media image to reduce stigma. Limitations include a large portion of included articles from the same contributors and a predominance of US-based studies, potentially affecting generalizability of findings. International perspectives should be included in future studies to ensure a more widely applicable understanding of DBS implementation challenges.
- 13 May 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessBarriers and facilitators to implementing deep brain stimulation for psychiatric disorders: a systematic review
Background Deep brain stimulation (DBS) is effective in treating severe obsessive-compulsive disorder (OCD) and treatment-resistant depression (TRD). However, patient referrals for DBS remain lower than expected based on prevalence and eligibility. Understanding the factors behind this gap is crucial for improving DBS implementation. This study aimed to identify key barriers and facilitators influencing DBS use for OCD and TRD. Insights from this research may help policymakers and clinicians address challenges, ultimately enhancing DBS accessibility and effectiveness for psychiatric disorders. Methods A systematic review was performed using four electronic databases until May 1st 2024 following PRISMA and ENTREQ guidelines. Eligible for inclusion were quantitative and qualitative studies describing facilitators or barriers for implementing DBS in psychiatry. Results We included 28 studies, out of which 11 in TRD, 5 in OCD and 12 in both, and revealed a spectrum of barriers, including ethical concerns, safety issues, stigma and knowledge gaps. Promising facilitators include educational initiatives, specialized psychiatric DBS care and stakeholder engagement. Discussion This first systematic review provides a comprehensive overview of barriers and facilitators affecting DBS implementation for OCD and TRD. Key areas include establishing consensus on treatment resistance, refining referral guidelines, addressing knowledge gaps among clinicians—such as psychiatrists unfamiliar with neurosurgical psychiatric treatments—and improving DBS’s media image to reduce stigma. Limitations include a large portion of included articles from the same contributors and a predominance of US-based studies, potentially affecting generalizability of findings. International perspectives should be included in future studies to ensure a more widely applicable understanding of DBS implementation challenges.
- Open Access
- 8 February 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
The role of lipids in neuromodulation for psychiatric disorders: A narrative review
Lipids are highly abundant in the brain and play key roles in membrane regulation, neurotransmission, neurogenesis, and inflammation. The same processes are involved in neuromodulation mechanisms. While neuromodulation therapies have shown promising outcomes for treatment-resistant psychiatric disorders, the factors determining individual variability in treatment response remain poorly understood. Furthermore, the potential impact of neurometabolic factors in predicting response has been largely overlooked. This narrative review aims to evaluate the role of lipids in psychiatric neuromodulation. Particularly glycerophospholipids, sphingolipids and polyunsaturated fatty acids (PUFAs) have been described as important mediators. Current evidence suggests a bidirectional relationship between lipids and neuromodulation therapies such as electroconvulsive therapy (ECT), and repetitive transcranial magnetic stimulation (rTMS). Neuromodulation effects are associated with lipid metabolism changes, including phospholipids, sphingolipids, and fatty acids. ECT is associated with an increase in lipid peroxidation and alterations of cholesterol and fatty acid levels, while rTMS is associated with normalization of sphingolipids and phospholipids levels. Solely one study investigated the relation between deep brain stimulation and lipids, showing an association with sphingolipid metabolism. To our knowledge, this is the first comprehensive review to consolidate findings on the relationship between lipids and neuromodulation. By mapping this emerging field, these findings might be a first step towards investigating whether lipids could be a potential biomarker for response prediction in the future. As most findings are preliminary, with variability across studies, further investigation is warranted and current findings should be interpreted in the context of their limitations.
- 8 February 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessThe role of lipids in neuromodulation for psychiatric disorders: A narrative review
Lipids are highly abundant in the brain and play key roles in membrane regulation, neurotransmission, neurogenesis, and inflammation. The same processes are involved in neuromodulation mechanisms. While neuromodulation therapies have shown promising outcomes for treatment-resistant psychiatric disorders, the factors determining individual variability in treatment response remain poorly understood. Furthermore, the potential impact of neurometabolic factors in predicting response has been largely overlooked. This narrative review aims to evaluate the role of lipids in psychiatric neuromodulation. Particularly glycerophospholipids, sphingolipids and polyunsaturated fatty acids (PUFAs) have been described as important mediators. Current evidence suggests a bidirectional relationship between lipids and neuromodulation therapies such as electroconvulsive therapy (ECT), and repetitive transcranial magnetic stimulation (rTMS). Neuromodulation effects are associated with lipid metabolism changes, including phospholipids, sphingolipids, and fatty acids. ECT is associated with an increase in lipid peroxidation and alterations of cholesterol and fatty acid levels, while rTMS is associated with normalization of sphingolipids and phospholipids levels. Solely one study investigated the relation between deep brain stimulation and lipids, showing an association with sphingolipid metabolism. To our knowledge, this is the first comprehensive review to consolidate findings on the relationship between lipids and neuromodulation. By mapping this emerging field, these findings might be a first step towards investigating whether lipids could be a potential biomarker for response prediction in the future. As most findings are preliminary, with variability across studies, further investigation is warranted and current findings should be interpreted in the context of their limitations.
- Open Access
- 15 August 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-7
Efficacy and safety of deep brain stimulation for treatment-refractory anorexia nervosa: a systematic review and meta-analysis
Background: Several pioneering studies investigated deep brain stimulation (DBS) in treatment-refractory anorexia nervosa (AN) patients, but overall effects remain yet unclear. Aim of this study was to obtain estimates of efficacy of DBS in AN-patients using meta-analysis. Methods: We searched three electronic databases until 1st of November 2021, using terms related to DBS and AN. We included trials that investigated the clinical effects of DBS in AN-patients. We obtained data including psychiatric comorbidities, medication use, DBS target, and study duration. Primary outcome was Body Mass Index (BMI), secondary outcome was quality of life, and the severity of psychiatric symptoms, including eating disorder, obsessive-compulsive, depressive, and anxiety symptoms. We assessed the risk of bias using the ROBINS-I tool. Results: Four studies were included for meta-analysis, with a total of 56 patients with treatment-refractory AN. Follow-up ranged from 6–24 months. Random effects meta-analysis showed a significant increase in BMI following DBS, with a large effect size (Hedges’s g = 1 ∙ 13; 95% CI = 0 ∙ 80 to 1 ∙ 46; Z-value = 6 ∙ 75; P < 0 ∙ 001), without heterogeneity (I2 = 0 ∙ 00, P = 0 ∙ 901). Random effects meta-analysis also showed a significant increase in quality of life (Hedges’s g = 0 ∙ 86; 95% CI = 0 ∙ 44 to 1 ∙ 28; Z-value = 4 ∙ 01, P < 0 ∙ 001). Furthermore, DBS decreased the severity of psychiatric symptoms (Hedges’s g = 0 ∙ 89; 95% CI = 0 ∙ 57 to 1 ∙ 21; Z-value = 5 ∙ 47; P < 0 ∙ 001, I2 = 4 ∙ 29, P = 0 ∙ 371). Discussion: In this first meta-analysis, DBS showed statistically large beneficial effects on weight restoration, quality of life, and reduction of psychiatric symptoms in patients with treatment-refractory AN. These outcomes call for more extensive naturalistic studies to determine the clinical relevance for functional recovery. This study is preregistered in PROSPERO,CRD42022295712.
- 15 August 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-7
Open AccessEfficacy and safety of deep brain stimulation for treatment-refractory anorexia nervosa: a systematic review and meta-analysis
Background: Several pioneering studies investigated deep brain stimulation (DBS) in treatment-refractory anorexia nervosa (AN) patients, but overall effects remain yet unclear. Aim of this study was to obtain estimates of efficacy of DBS in AN-patients using meta-analysis. Methods: We searched three electronic databases until 1st of November 2021, using terms related to DBS and AN. We included trials that investigated the clinical effects of DBS in AN-patients. We obtained data including psychiatric comorbidities, medication use, DBS target, and study duration. Primary outcome was Body Mass Index (BMI), secondary outcome was quality of life, and the severity of psychiatric symptoms, including eating disorder, obsessive-compulsive, depressive, and anxiety symptoms. We assessed the risk of bias using the ROBINS-I tool. Results: Four studies were included for meta-analysis, with a total of 56 patients with treatment-refractory AN. Follow-up ranged from 6–24 months. Random effects meta-analysis showed a significant increase in BMI following DBS, with a large effect size (Hedges’s g = 1 ∙ 13; 95% CI = 0 ∙ 80 to 1 ∙ 46; Z-value = 6 ∙ 75; P < 0 ∙ 001), without heterogeneity (I2 = 0 ∙ 00, P = 0 ∙ 901). Random effects meta-analysis also showed a significant increase in quality of life (Hedges’s g = 0 ∙ 86; 95% CI = 0 ∙ 44 to 1 ∙ 28; Z-value = 4 ∙ 01, P < 0 ∙ 001). Furthermore, DBS decreased the severity of psychiatric symptoms (Hedges’s g = 0 ∙ 89; 95% CI = 0 ∙ 57 to 1 ∙ 21; Z-value = 5 ∙ 47; P < 0 ∙ 001, I2 = 4 ∙ 29, P = 0 ∙ 371). Discussion: In this first meta-analysis, DBS showed statistically large beneficial effects on weight restoration, quality of life, and reduction of psychiatric symptoms in patients with treatment-refractory AN. These outcomes call for more extensive naturalistic studies to determine the clinical relevance for functional recovery. This study is preregistered in PROSPERO,CRD42022295712.